HTML Microdata document

This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n12	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/kegg-drug/
n16	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/pubchem-substance/
n2	http://linked.opendata.cz/resource/drugbank/drug/
n15	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/drugbank/
dcterms	http://purl.org/dc/terms/
n8	http://linked.opendata.cz/resource/AHFS/
n25	http://linked.opendata.cz/resource/mesh/concept/
foaf	http://xmlns.com/foaf/0.1/
n13	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/national-drug-code-directory/
n23	http://linked.opendata.cz/resource/drugbank/dosage/
n27	http://linked.opendata.cz/resource/drugbank/mixture/
n21	http://www.rxlist.com/
n26	http://bio2rdf.org/drugbank:
n14	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/chebi/
adms	http://www.w3.org/ns/adms#
n11	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n19	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/pharmgkb/
n6	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/wikipedia/
owl	http://www.w3.org/2002/07/owl#
n24	http://linked.opendata.cz/ontology/mesh/
n3	http://linked.opendata.cz/ontology/drugbank/
n4	http://linked.opendata.cz/resource/drugbank/property/
n22	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/bindingdb/
n18	http://www.drugs.com/pro/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB06708/identifier/pubchem-compound/
xsdh	http://www.w3.org/2001/XMLSchema#
n7	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB06708
rdf:type: n3:Drug
n3:description: Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
n3:dosage: n23:271B5026-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # Artemether and Lumefantrine (2010). AHFS Drug Information [Electronic versionb]. Retrieved October 24, 2010. # Artemether/Lumefantrine (2010). DrugPoints® System [Electronic version]. Retrieved October 24, 2010. # Novartis. Coartem (artemether/lumefantrine) tablets prescribing information. East Hanover, NJ; 2010 Feb.
n3:group: approved
n3:halfLife: ~ 4.5 days
n3:indication: Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
owl:sameAs: n11:DB06708 n26:DB06708
dcterms:title: Lumefantrine
adms:identifier: n6:Lumefantrine n12:D03821 n13:0078-0568-45 n14:156095 n15:DB06708 n16:99443260 n19:PA165111722 n20:6437380 n22:50123012
n3:mechanismOfAction: The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. However, available data suggest that lumefantrine inhibits the formation of β-hematin by forming a complex with hemin and inhibits nucleic acid and protein synthesis.
n3:synonym: DL-Benflumelol 2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol Benflumetol Lumefantrine 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanol (+-)-2,7-Dichloro-9-((Z)-P-chlorobenzylidene)-alpha-((dibutylamino)methyl)fluorene-4-methanol
n3:toxicity: Common side effects of combination artemether/lumefantrine therapy in adults include headache, anorexia, dizziness, and asthenia. Common side effects in children include pyrexia, cough, vomiting, anorexia, and headache. Possible serious adverse effects include QT prolongation, bullous eruption, urticaria, splenomegaly (9%), hepatomegaly (adults, 9%; children, 6%), hypersensitivty reaction, and angioedema.
n7:hasAHFSCode: n8:8-30-08
n3:foodInteraction: Grapefruit juice may increase the toxicity of artemether and lumefantrine by inhibiting their metabolism. Take with food as food increases the absorption of lumefantrine and artemether.
n3:mixture: n27:271B5025-363D-11E5-9242-09173F13E4C5
n3:proteinBinding: 99.7% bound
n24:hasConcept: n25:M0267388
foaf:page: n18:coartem.html n21:coartem-drug.htm
n3:IUPAC-Name: n4:271B502B-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B5031-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B5030-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B502D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B502E-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B502F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B5029-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B502A-363D-11E5-9242-09173F13E4C5 n4:271B5027-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B5028-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count: n4:271B5037-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B5038-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B5032-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B5033-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B5035-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B5034-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B5036-363D-11E5-9242-09173F13E4C5
n3:absorption: Food increases absorption.
n3:affectedOrganism: Plasmodium
n3:casRegistryNumber: 82186-77-4
n3:category
n3:Bioavailability: n4:271B503D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B503F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B5040-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B503C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B503B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B503E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B502C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B5039-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B503A-363D-11E5-9242-09173F13E4C5